Use of Probe Drugs as Predictors of Drug Metabolism in Humans
Data up to Jan 2025
Total Citations Per Year
Abstract
References (51)
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
1994 • 958 citations
Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.
1994 • 749 citations
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
1993 • 652 citations
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
1980 • 544 citations
Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.
1992 • 536 citations
Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1
1990 • 535 citations
Biochemistry and molecular biology of the human CYP2C subfamily
1994 • 534 citations
Geographical/Interracial Differences in Polymorphic Drug Oxidation
1995 • 431 citations
Noninvasive tests of CYP3A enzymes
1994 • 414 citations
Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.
1994 • 350 citations
Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients.
1989 • 349 citations
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
1995 • 310 citations
Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by the erythromycin breath test
1994 • 291 citations
The use of caffeine for enzyme assays: A critical appraisal
1993 • 282 citations
Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.
1987 • 281 citations
Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin
1996 • 280 citations
Rifampin drastically reduces plasma concentrations and effects of oral midazolam
1996 • 238 citations
Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.
1988 • 199 citations
Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine
1990 • 196 citations
Interphenotype differences in disposition and effect on gastrin levels of omeprazole—suitability of omeprazole as a probe for CYP2C19.
1995 • 187 citations
Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva
1994 • 179 citations
Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation*
1996 • 172 citations
Advances in Drug Metabolism in Man
1995 • 167 citations
“It's the genes, stupid” Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism
1995 • 162 citations
Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities
1982 • 160 citations
Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms*
1995 • 154 citations
Expression of cytochrome P450 3A in amphibian, rat, and human kidney
1992 • 149 citations
Extremely Rapid Hydroxylation of Debrisoquine
1985 • 144 citations
Assessment of Liver Metabolic Function
1994 • 138 citations
Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men
1993 • 137 citations
The erythromycin breath test predicts the clearance of midazolam*
1995 • 132 citations
The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease
1992 • 132 citations
Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations
1996 • 128 citations
Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol
1992 • 120 citations
Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1
1995 • 111 citations
Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test
1994 • 107 citations
Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo*
1995 • 101 citations
The erythromycin breath test as a predictor of cyclosporine blood levels
1990 • 99 citations
Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population
1994 • 90 citations
Rapid detection of CYP2D6 null alleles by long distance-and multiplex-polymerase chain reaction
1996 • 86 citations
Drug Interactions and the Cytochrome P450 System
1995 • 86 citations
Human liver microsomal N-hydroxylation of dapsone by cytochrome P-4503A4.
1992 • 80 citations
Caffeine as a probe for CYP1A2 activity
1994 • 74 citations
Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation.
1995 • 71 citations
The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects
1990 • 64 citations
Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients
1992 • 58 citations
Metabolism of cytochrome P4503A substrates in vivo administered by the same route: Lack of correlation between alfentanil clearance and erythromycin breath test
1994 • 57 citations
P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients
1994 • 54 citations
Caffeine as a metabolic probe: a comparison of the metabolic ratios used to assess CYP1A2 activity.
1995 • 37 citations
Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine*
1996 • 35 citations
Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: Comparison of sparteine and dextromethorphan*
1996 • 25 citations